Acomplia - Rimonabant is a new miraculous multifunctional diet pill.

According to a report published by the Journal of the American Medical Association:

* produces sustained weight loss
* helps to quit smoking
* improves blood makers
* improves high-density lipoprotein (HDL) cholesterol and triglyceride levels

What is Acomplia - Rimonabant?

* Acomplia - Rimonabant is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).
* Acomplia - Rimonabant is used in the treatment of obesity and related conditions.

How does Acomplia - Rimonabant work?

* Acomplia - Rimonabant acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1.
* Acomplia - Rimonabant switches off the same brain circuits that make people hungry when they smoke cannabis.
* CB1 receptor blockade with Acomplia - Rimonabant acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.

What is Acomplia - Rimonabant used for?

* Acomplia - Rimonabant is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood.
* Sanofi argues that Acomplia - Rimonabant can also prevent the risk of cardiovascular disease.
* Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.

Does Acomplia - Rimonabant also aid smoking cessation?

* Acomplia - Rimonabant has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
* Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia - Rimonabant for use in smoking cessation. An approvable letter was however issued for Acomplia - Rimonabant for use in weight management.

Acomplia - Rimonabant has just been approved in the European Union. Is Acomplia - Rimonabant approved in the United States?

* No. Sanofi is still awaiting U.S. marketing go-ahead which it has said could come by the end of this year.
* U.S. health authorities have asked Sanofi for more information on Acomplia - Rimonabant.
* Acomplia - Rimonabant received European Union marketing approval in June 2006.
* The first launch will take place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi.

What were the results of Acomplia - Rimonabant Clinical trial studies?

* In clinical studies, Acomplia - Rimonabant has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5.
* Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia - Rimonabant 20mg was beyond that expected from weight loss alone.

What are the side-effects of Acomplia - Rimonabant?

* Side effects in the trial on Acomplia - Rimonabant in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.

What is the shelf life of the pills?

* The expiry date is mentioned on each blister. It is different for different batches. The shelf life is 2 years from the date of manufacture and would differ from batch to batch depending on when they were manufactured.